Press release from Business Wire
DexCom Announces Upcoming Conference Presentations
Friday, November 01, 2013
DexCom Announces Upcoming Conference Presentations08:30 EDT Friday, November 01, 2013
SAN DIEGO (Business Wire) -- DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on DexCom at the following upcoming investor conferences:
- Steve Pacelli, EVP, Strategy and Corporate Development, will present an update on DexCom at the Stephens Fall Investment Conference in New York, New York on Tuesday, November 12, 2013 at 9:00 a.m. (EST). The presentation, which will occur live at The New York Palace Hotel, will be concurrently webcast.
- Kevin Sayer, President and Chief Operating Officer, will present an update on DexCom at the 2013 Credit Suisse Healthcare Conference in Scottsdale, Arizona on Wednesday, November 13, 2013 at 3:30 p.m. (MST). The presentation, which will occur live at The Phoenician, will be concurrently webcast.
- Terry Gregg, Chief Executive Office, will present an update on DexCom at the Canaccord Genuity Medical Technology & Diagnostics Forum in New York, New York, on Thursday, November 14, 2013 at 9:30 a.m. (EST). The presentation, which will occur live at the Westin Grand Central, will be concurrently webcast.
The link to each webcast will be available on the DexCom website at www.dexcom.com by navigating to “About,” then “Investor Relations,” and then “Events and Webcasts,” and the presentations will be archived there for future reference.
About DexCom, Inc.
DexCom, Inc., headquartered in San Diego, California, is developing and marketing continuous glucose monitoring systems for ambulatory use by patients and by healthcare providers in the hospital.
Cautionary Statement Regarding Forward Looking Statements
DexCom is a medical device company with a limited operating history. Successful commercialization of the company's products is subject to numerous risks and uncertainties, including a lack of acceptance in the marketplace by physicians and patients, the inability to manufacture products in commercial quantities at an acceptable cost, possible delays in the company's development programs, the inability of patients to receive reimbursement from third-party payors and inadequate financial and other resources. Certain of these risks and uncertainties, in addition to other risks, are more fully described in the company's quarterly report on Form 10-Q for the quarter ended June 30, 2013, as filed with the Securities and Exchange Commission on August 7, 2013.
Steven R. Pacelli
Executive Vice President, Strategy and Corporate Development